Counterfeit and grey-market supply

Two problems that get called one thing

Counterfeit medicine is defined by deception. The federal drug agency describes counterfeit, fake or falsified medicines as products passed off as authentic. They may contain the wrong ingredients, too much or too little active ingredient, none at all, or other harmful ingredients.

Grey-market supply is a different failure. The product may be exactly what it says it is. What is missing is the chain of custody: who made it, who held it, at what temperature, and whether anyone with a license was ever accountable for it.

A counterfeit is a lie about contents. A grey-market vial may be a silence about history.

They are worth separating because the checks that catch one do not catch the other. A great deal of the peptide market is the second thing, while conversation about it borrows the language of the first.

The closed system, and what "closed" means

The agency describes the United States drug supply as among the safest in the world, and attributes that to federal and state laws creating a closed drug distribution system.

Closed means every hand a medication passes through is a licensed, recorded one. Manufacturer, authorized distributor, licensed pharmacy, patient. Each link is accountable and each transfer leaves a record.

Its consumer guidance follows directly from that architecture: buy only from state-licensed pharmacies.

Everything outside that chain is, by definition, outside the system that makes the assurance possible. That is true whether the seller is dishonest or entirely sincere, because the assurance was never about sincerity.

The case that breaks the easy heuristics

The most instructive documented episode in this drug class is not about an overseas website. It is about the closed chain itself.

The agency has published alerts on counterfeit semaglutide injection sold under an approved brand name. In its most recent entry it reported seizing counterfeit units distributed illegally outside the manufacturer's authorized supply chain. It then stated plainly that the seized counterfeit products were in the legitimate United States drug supply chain.

Two details in that alert dismantle the checks people reach for first.

The counterfeit units carried a lot number that is also a genuine lot number. Reading a lot number and finding it real proves nothing.

And the way to tell them apart was the position of the expiry and lot text on the pen label, not the ingredients, the packaging quality or the price. The tell was typography.

The agency also said testing and analysis of the seized products were underway, meaning it did not yet know what was inside them. When the regulator with the seized units in hand cannot say what is in the vial, a purchaser holding one certainly cannot.

What that case does and does not show

It shows that a counterfeit reaching a legitimate pharmacy shelf is a documented event rather than a hypothetical, and that it was caught by the manufacturer and the regulator rather than by a patient.

It does not show that pharmacies are unsafe. It shows the opposite of the usual moral: the detection, the seizure, the public alert and the lot-level identification all exist because the product was inside a system that keeps records.

The agency also noted adverse event reports associated with that lot, while stating they were associated with authentic product and that none appeared to be associated with the counterfeit. That is a careful distinction, and it is the kind that disappears when a case is retold.

The honest reading is not that the chain failed. It is that the chain is what made the failure visible at all.

The signs the agency actually publishes

The consumer guidance lists what to notice, and the list is unglamorous.

A drug or its packaging that looks different from what you normally receive. A new or unusual effect after using it. Packaging that is broken, damaged, in a foreign language, undated or expired.

On the seller side, the safe signs are four. A pharmacy that always requires a prescription. One that publishes a physical address and telephone number in the United States. One with a licensed pharmacist available to answer questions. And one licensed with a state board of pharmacy.

The warning signs are the mirror image. No prescription required. Not licensed in the United States or by your state board. No pharmacist available. Deep discounts or prices that seem too good to be true. Charges for products never ordered. No clear written protection for your personal and financial information.

That first warning sign is the one worth sitting with in this market, because a seller that does not require a prescription is not a pharmacy with lax standards. It is a different kind of business.

Where research-use-only vials sit

A vial sold under a research-use-only label is not inside the closed system, and that is not an accusation. It is the arrangement.

There is no prescription, no dispensing pharmacy, no pharmacist and no dispensing record. The distribution chain the agency describes is not a chain the transaction is part of.

That does not mean the contents are wrong. It means there is no licensed party who was accountable for them, and no record for anyone to check afterward, including you.

Documents that arrive with such a vial describe the seller's own account of what it holds. They are made by the party selling it, which is a different thing from a chain of custody.

The import overlap

The two problems meet at the border, and the agency says so.

Its counterfeit guidance states that many counterfeit drugs are made abroad, and arrive in the United States through the mail or are smuggled into the country. The agency adds that it works with customs on the areas presenting the most substantial threat.

The statute is unambiguous at that point. If an article appears to be a counterfeit drug, it shall be refused admission.

A parcel that arrived is therefore not a finding about the parcel. It is the absence of an interception, which is not the same thing.

What is actually checkable

Very little of this is checkable by looking at a vial, which is the uncomfortable part. Most of it is checkable by looking at the transaction.

Was a prescription required? Is a pharmacy named, and does it appear in your state board of pharmacy's license database? Is there a physical United States address and a phone number that reaches a person? Is a pharmacist reachable?

Does the packaging look like what a pharmacy sends, and does the label carry a patient name, a prescriber, a strength and directions?

And where something does look wrong, the agency publishes reporting routes for suspected counterfeits, for adverse effects, and for websites selling medicine unlawfully.

None of those checks inspects the contents. They establish whether anyone with a license was accountable for them, which is the question the closed system was built to answer.

Sources

Each document below is named as it names itself, with the date printed on that document rather than the day it was read.

1. Counterfeit Medicine — U.S. Food and Drug Administration, December 2025
2. FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain — U.S. Food and Drug Administration, December 2025
3. BeSafeRx: Considering an Online Pharmacy? — U.S. Food and Drug Administration, September 2020
4. United States Code Title 21, Section 381(a), Imports and exports, 2024 Main Edition — Office of the Law Revision Counsel, U.S. House of Representatives, January 2025